CD BioGlyco is at the forefront of developing efficient methods for Glycosylation Inhibitor Development. We constantly strive to improve the yield and sustainability of synthesis processes, utilizing cutting-edge technologies and sustainable practices. Our objective is to deliver the utmost-quality DS inhibitor development service to you. In addition to synthesis, we also prioritize the evaluation of pharmacokinetics and toxicity of DS inhibitors. Our dedicated researchers conduct thorough studies to determine the metabolic pathways, drug concentrations, and potential toxic risks associated with DS inhibitors. Our DS inhibitor development services are divided into but are not limited to the following directions:
Fig.1 Routine procedures for inhibitor development. (CD BioGlyco)
The biosynthesis and regulatory mechanisms of DS in vivo are complex and include the involvement and regulation of multiple enzymes. Therefore, understanding its mechanism of action and its interactions with other biomolecules is a complex challenge. CD BioGlyco is well-equipped to assist you in overcoming these challenges, thanks to our extensive experience in the field. Our team of experts has a deep understanding of the complex mechanisms involved in DS biosynthesis and regulation. We have conducted extensive research to unravel the intricate workings of DS and its interactions with other biomolecules.
Fig.2 The structure of CS/DS. (Wang, et al., 2020)
CD BioGlyco has developed a range of comprehensive solutions to facilitate the development of DS inhibitors. Our primary goal is to assist academic laboratories and industries in investigating the biological and pharmaceutical effects of saccharide-based DS inhibitors. If you have any questions about our company and products, please feel free to contact us.